INmune Bio, Inc. is developing therapies that harness the patient's immune system to treat cancer. INmune Bio, a cancer immunotherapy startup company, focused on developing therapies that prime natural killer (NK) cells to attack cancer. INmune is targeting residual disease - the cancer cells that survive initial treatments that return to cause the cancer relapse which may cause death.
INmune Bio Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/inmune-bio-inc” connections=”true” suffix=””]
In Oct 2017, INmune Bio inlicensed INB03, a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells, from Xencor, Inc. The terms of the deal have not been made public. Xencor received an ownership position in INmune Bio and a seat on the Board of Directors.